SCHEMBL18512781

SCHEMBL18512781

CC(=O)O[C@H]1C(n2ccc(=O)[nH]c2=O)O[C@H](CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)[C@H]1C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.43
DUT P33316 1/20 0.41
P2RY2 P41231 6/20 0.40
SLC28A1 O00337 1/20 0.39
SLC28A2 O43868 1/20 0.39
SLC29A1 Q99808 1/20 0.39
SLC28A3 Q9HAS3 1/20 0.39
P2RY12 Q9H244 4/20 0.39
P2RY14 Q15391 2/20 0.39
P2RY6 Q15077 3/20 0.39
NT5E P21589 1/20 0.39
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
P2RY4 P51582 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17198586 1.00 TDP1 (0.43) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL5960185 0.90 LMNA (0.42) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL18503491 0.90 TDP1 (0.41) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL17198561 0.90 TDP1 (0.40) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL17198440 0.90 TDP1 (0.43) TDP1DUTP2RY2P2RY12P2RY14
SCHEMBL18503502 0.88 NT5E (0.42) TDP1DUTP2RY2P2RY12P2RY14
SCHEMBL17198609 0.88 NT5E (0.42) TDP1DUTP2RY2P2RY12P2RY14
SCHEMBL18512777 0.88 P2RY2 (0.39) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL17198611 0.88 P2RY2 (0.39) TDP1DUTP2RY2SLC28A1SLC28A2
SCHEMBL18512723 0.87 SLC28A1 (0.49) P2RY2SLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202411-B2 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (US) 2019-02-12 US disclosed
US-20170044205-A1 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS, INC. 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044205-A1 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV RB1, NSUN2, METTL3 TDP1 625/4885DUT 208/4885P2RY2 390/4885
US-10202411-B2 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV RB1, NSUN2, METTL3 TDP1 635/4885DUT 201/4885P2RY2 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.